Format
Sort by

Send to

Choose Destination

Links from Books

Items: 12

1.

Promising molecular targeted therapies in breast cancer.

Munagala R, Aqil F, Gupta RC.

Indian J Pharmacol. 2011 May;43(3):236-45. doi: 10.4103/0253-7613.81497.

2.

Signal transduction by vascular endothelial growth factor receptors.

Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L.

Biochem J. 2011 Jul 15;437(2):169-83. doi: 10.1042/BJ20110301. Review.

PMID:
21711246
3.

Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.

Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T.

Curr Med Chem. 2011;18(21):3136-55. Review.

PMID:
21671856
4.

Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel.

Cho EJ, Yang J, Mohamedali KA, Lim EK, Kim EJ, Farhangfar CJ, Suh JS, Haam S, Rosenblum MG, Huh YM.

Invest Radiol. 2011 Jul;46(7):441-9. doi: 10.1097/RLI.0b013e3182174fad.

PMID:
21512397
5.

Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature.

Backer MV, Hamby CV, Backer JM.

Adv Genet. 2009;67:1-27. doi: 10.1016/S0065-2660(09)67001-2. Review.

PMID:
19914448
6.

EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.

Press MF, Lenz HJ.

Drugs. 2007;67(14):2045-75. Review.

PMID:
17883287
7.

Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.

Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, Vogel H, Hou LC, Tse V, Rosenblum MG, Chen X.

J Nucl Med. 2007 Mar;48(3):445-54.

8.

The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.

Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG.

Neoplasia. 2005 Oct;7(10):912-20.

9.

Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein.

Akiyama H, Mohamedali KA, E Silva RL, Kachi S, Shen J, Hatara C, Umeda N, Hackett SF, Aslam S, Krause M, Lai H, Rosenblum MG, Campochiaro PA.

Mol Pharmacol. 2005 Dec;68(6):1543-50.

10.

The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.

Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG.

Neoplasia. 2005 May;7(5):486-96.

11.

Vascular targeting agents as cancer therapeutics.

Thorpe PE.

Clin Cancer Res. 2004 Jan 15;10(2):415-27. Review.

12.

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.

Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG.

Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7866-71. Erratum in: Proc Natl Acad Sci U S A 2002 Aug 6;99(16):10941.

Items per page

Supplemental Content

Support Center